ZA200301740B - HIV peptides from conserved regions in gas P17 and P24 and their application in e.g. vaccines. - Google Patents
HIV peptides from conserved regions in gas P17 and P24 and their application in e.g. vaccines. Download PDFInfo
- Publication number
- ZA200301740B ZA200301740B ZA200301740A ZA200301740A ZA200301740B ZA 200301740 B ZA200301740 B ZA 200301740B ZA 200301740 A ZA200301740 A ZA 200301740A ZA 200301740 A ZA200301740 A ZA 200301740A ZA 200301740 B ZA200301740 B ZA 200301740B
- Authority
- ZA
- South Africa
- Prior art keywords
- liquid
- solvent
- vapour
- pressure vessel
- vessel
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 239000002904 solvent Substances 0.000 claims description 59
- 239000007788 liquid Substances 0.000 claims description 42
- 239000002028 Biomass Substances 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 239000007921 spray Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 238000001704 evaporation Methods 0.000 claims description 9
- 230000008020 evaporation Effects 0.000 claims description 9
- 238000009834 vaporization Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000013022 venting Methods 0.000 claims 1
- 239000000047 product Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 238000009835 boiling Methods 0.000 description 11
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 4
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 4
- AWTOFSDLNREIFS-UHFFFAOYSA-N 1,1,2,2,3-pentafluoropropane Chemical compound FCC(F)(F)C(F)F AWTOFSDLNREIFS-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 3
- MSSNHSVIGIHOJA-UHFFFAOYSA-N pentafluoropropane Chemical compound FC(F)CC(F)(F)F MSSNHSVIGIHOJA-UHFFFAOYSA-N 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- FYIRUPZTYPILDH-UHFFFAOYSA-N 1,1,1,2,3,3-hexafluoropropane Chemical compound FC(F)C(F)C(F)(F)F FYIRUPZTYPILDH-UHFFFAOYSA-N 0.000 description 2
- NSGXIBWMJZWTPY-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropane Chemical compound FC(F)(F)CC(F)(F)F NSGXIBWMJZWTPY-UHFFFAOYSA-N 0.000 description 2
- UJPMYEOUBPIPHQ-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound CC(F)(F)F UJPMYEOUBPIPHQ-UHFFFAOYSA-N 0.000 description 2
- WXGNWUVNYMJENI-UHFFFAOYSA-N 1,1,2,2-tetrafluoroethane Chemical compound FC(F)C(F)F WXGNWUVNYMJENI-UHFFFAOYSA-N 0.000 description 2
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- GTLACDSXYULKMZ-UHFFFAOYSA-N pentafluoroethane Chemical compound FC(F)C(F)(F)F GTLACDSXYULKMZ-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- SUAMPXQALWYDBK-UHFFFAOYSA-N 1,1,1,2,2,3-hexafluoropropane Chemical compound FCC(F)(F)C(F)(F)F SUAMPXQALWYDBK-UHFFFAOYSA-N 0.000 description 1
- ZDCWZRQSHBQRGN-UHFFFAOYSA-N 1,1,1,2,3-pentafluoropropane Chemical compound FCC(F)C(F)(F)F ZDCWZRQSHBQRGN-UHFFFAOYSA-N 0.000 description 1
- WZLFPVPRZGTCKP-UHFFFAOYSA-N 1,1,1,3,3-pentafluorobutane Chemical compound CC(F)(F)CC(F)(F)F WZLFPVPRZGTCKP-UHFFFAOYSA-N 0.000 description 1
- MWDWMQNTNBHJEI-UHFFFAOYSA-N 1,1,2,3,3-pentafluoropropane Chemical compound FC(F)C(F)C(F)F MWDWMQNTNBHJEI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- 235000007129 Cuminum cyminum Nutrition 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 240000007232 Illicium verum Species 0.000 description 1
- 235000008227 Illicium verum Nutrition 0.000 description 1
- -1 R-227ea Chemical compound 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 240000006064 Urena lobata Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical class FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000012432 intermediate storage Methods 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Extraction Or Liquid Replacement (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20004413A NO314588B1 (no) | 2000-09-04 | 2000-09-04 | HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200301740B true ZA200301740B (en) | 2004-06-21 |
Family
ID=19911533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200301740A ZA200301740B (en) | 2000-09-04 | 2001-09-03 | HIV peptides from conserved regions in gas P17 and P24 and their application in e.g. vaccines. |
Country Status (20)
Country | Link |
---|---|
US (2) | US7009037B2 (ru) |
EP (2) | EP1322665B1 (ru) |
JP (2) | JP2004508381A (ru) |
CN (2) | CN1282656C (ru) |
AR (2) | AR033998A1 (ru) |
AT (1) | ATE406380T1 (ru) |
AU (3) | AU2001282706B2 (ru) |
BR (1) | BR0114036A (ru) |
CA (1) | CA2421193A1 (ru) |
DE (1) | DE60135564D1 (ru) |
EA (1) | EA006308B1 (ru) |
ES (1) | ES2312465T3 (ru) |
HK (1) | HK1059940A1 (ru) |
HU (1) | HUP0303134A3 (ru) |
MY (1) | MY136081A (ru) |
NO (1) | NO314588B1 (ru) |
NZ (2) | NZ524556A (ru) |
SK (1) | SK287917B6 (ru) |
WO (1) | WO2002020554A2 (ru) |
ZA (1) | ZA200301740B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023031579A1 (en) * | 2021-09-02 | 2023-03-09 | 113 Botanicals Limited | Extraction |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0108210A (pt) | 2000-02-04 | 2002-10-22 | Univ Duke | Vacina contra o vìrus da imunodeficiência humana |
EP2045282B1 (en) * | 2005-08-26 | 2011-03-23 | Novo Nordisk A/S | A method of modifying a macromolecular system |
FI120376B (fi) * | 2007-01-17 | 2009-09-30 | Next Biomed Technologies Nbt O | Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi |
FI120349B (fi) | 2007-03-07 | 2009-09-30 | Next Biomed Technologies Nbt O | Menetelmä fuusiopolypeptidin valmistamiseksi |
AP2857A (en) | 2008-09-09 | 2014-02-28 | Celebrity Biogens Llc | Bioactive composition for the treatment of the HIV/AIDS, method for manufacturing and using the same |
WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
US9733242B2 (en) | 2012-10-07 | 2017-08-15 | Sevident, Inc. | Devices for capturing analyte |
US9910040B2 (en) | 2012-07-09 | 2018-03-06 | Sevident, Inc. | Molecular nets comprising capture agents and linking agents |
FR2957933B1 (fr) * | 2010-03-24 | 2012-04-27 | Seppic Sa | Vaccin vivant pour maladies aviaires |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
EP3338798A1 (en) * | 2011-01-06 | 2018-06-27 | Bionor Immuno AS | Multimeric peptide |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
WO2013182661A1 (en) | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
EP2976325B1 (en) | 2013-03-21 | 2017-03-01 | Sanofi-Aventis Deutschland GmbH | Synthesis of cyclic imide containing peptide products |
CA2907454C (en) | 2013-03-21 | 2021-05-04 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
WO2017007994A1 (en) | 2015-07-08 | 2017-01-12 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
CN111569090A (zh) | 2016-01-15 | 2020-08-25 | 美国基因技术国际有限公司 | 用于活化γ-δ T细胞的方法和组合物 |
US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
JP7153332B2 (ja) | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Hivワクチン接種および免疫療法 |
JP7017247B2 (ja) | 2016-03-09 | 2022-02-08 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | がんを処置するための組み合わせベクターおよび方法 |
WO2017213697A1 (en) | 2016-06-08 | 2017-12-14 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
JP6971492B2 (ja) | 2016-07-08 | 2021-11-24 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Hiv予備免疫化および免疫療法 |
JP7176756B2 (ja) | 2016-07-21 | 2022-11-22 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | パーキンソン病を処置するためのウイルスベクター |
EP3607072A4 (en) | 2017-04-03 | 2021-01-06 | American Gene Technologies International Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF PHENYLCETONURISM |
US11352646B2 (en) | 2018-11-05 | 2022-06-07 | American Gene Technologies International Inc. | Vector system for expressing regulatory RNA |
RU2727673C1 (ru) * | 2019-08-09 | 2020-07-22 | Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства | Антитела против белка р17 ВИЧ-1 субтипа А |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ235538A (en) * | 1989-10-12 | 1992-06-25 | Viral Technologies Inc | Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera |
SE468168B (sv) | 1990-02-20 | 1992-11-16 | Replico Medical Ab | Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov |
DE4039925A1 (de) * | 1990-12-14 | 1992-06-17 | Behringwerke Ag | Ausgewaehlte peptide des gruppenspezifischen antigens (gag) von humanem immundefizienzvirus (hiv), ihre herstellung und verwendung |
SE9101863D0 (sv) * | 1991-06-13 | 1991-06-13 | Replico Medical Ab | Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar |
EP0907740A1 (en) | 1997-01-02 | 1999-04-14 | Universidade Federal De Minas Gerais | THE PROCESS FOR EXPRESSION AND PRODUCTION OF RECOMBINANT PROTEIN HYBRID PROTEIN (p24/p17) DERIVED FROM HUMAN IMMUNODEFICIENCY VIRUSES (HIV-1) |
GB9703802D0 (en) * | 1997-02-24 | 1997-04-16 | Kingsman Susan M | Anti-hiv peptides and proteins |
US5972339A (en) | 1997-11-13 | 1999-10-26 | The General Hospital Corporation | Method of eliciting anti-HIV-1 helper T cell responses |
EP1078092B1 (en) | 1998-05-13 | 2011-08-03 | Epimmune Inc. | Expression vectors for stimulating an immune response and methods of using the same |
NO311807B1 (no) * | 1999-03-04 | 2002-01-28 | Bionor Immuno As | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
-
2000
- 2000-09-04 NO NO20004413A patent/NO314588B1/no not_active IP Right Cessation
-
2001
- 2001-09-03 NZ NZ524556A patent/NZ524556A/en not_active IP Right Cessation
- 2001-09-03 ZA ZA200301740A patent/ZA200301740B/en unknown
- 2001-09-03 WO PCT/NO2001/000362 patent/WO2002020554A2/en active IP Right Grant
- 2001-09-03 AU AU2001282706A patent/AU2001282706B2/en not_active Ceased
- 2001-09-03 AT AT01961444T patent/ATE406380T1/de not_active IP Right Cessation
- 2001-09-03 AU AU8270601A patent/AU8270601A/xx active Pending
- 2001-09-03 EP EP01961444A patent/EP1322665B1/en not_active Expired - Lifetime
- 2001-09-03 CN CNB018157424A patent/CN1282656C/zh not_active Expired - Fee Related
- 2001-09-03 EP EP07014954A patent/EP1878742A3/en not_active Withdrawn
- 2001-09-03 HU HU0303134A patent/HUP0303134A3/hu unknown
- 2001-09-03 ES ES01961444T patent/ES2312465T3/es not_active Expired - Lifetime
- 2001-09-03 DE DE60135564T patent/DE60135564D1/de not_active Expired - Lifetime
- 2001-09-03 JP JP2002525174A patent/JP2004508381A/ja active Pending
- 2001-09-03 CN CNA2006101517487A patent/CN101104636A/zh active Pending
- 2001-09-03 CA CA002421193A patent/CA2421193A1/en not_active Abandoned
- 2001-09-03 NZ NZ535148A patent/NZ535148A/en not_active IP Right Cessation
- 2001-09-03 SK SK402-2003A patent/SK287917B6/sk not_active IP Right Cessation
- 2001-09-03 US US10/129,331 patent/US7009037B2/en not_active Expired - Fee Related
- 2001-09-03 BR BR0114036-1A patent/BR0114036A/pt not_active IP Right Cessation
- 2001-09-03 EA EA200300336A patent/EA006308B1/ru not_active IP Right Cessation
- 2001-09-04 MY MYPI20014139A patent/MY136081A/en unknown
- 2001-09-04 AR ARP010104196A patent/AR033998A1/es active IP Right Grant
-
2004
- 2004-04-22 HK HK04102846A patent/HK1059940A1/xx not_active IP Right Cessation
-
2005
- 2005-08-26 US US11/211,576 patent/US7612168B2/en not_active Expired - Fee Related
-
2007
- 2007-06-13 AU AU2007202739A patent/AU2007202739B2/en not_active Ceased
-
2008
- 2008-12-03 AR ARP080105262A patent/AR071262A2/es not_active Application Discontinuation
-
2011
- 2011-06-08 JP JP2011128389A patent/JP2011219481A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023031579A1 (en) * | 2021-09-02 | 2023-03-09 | 113 Botanicals Limited | Extraction |
GB2610556A (en) * | 2021-09-02 | 2023-03-15 | 113 Botanicals Ltd | Extraction |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200301740B (en) | HIV peptides from conserved regions in gas P17 and P24 and their application in e.g. vaccines. | |
US6589422B2 (en) | Apparatus and method for extracting biomass | |
EP1210161B1 (en) | Apparatus and method for extracting biomass | |
WO2001017639A1 (en) | Apparatus and method for separating mixed liquids | |
US6676838B2 (en) | Apparatus and methods for removing solvent residues | |
US6667015B1 (en) | Apparatus and method for extracting biomass | |
AU766475C (en) | Apparatus and method for removing solvent residues | |
EP1345665B1 (en) | Apparatus and method for extracting biomass | |
WO2001017640A1 (en) | Apparatus and method for reducing residual solvent levels |